Synaptogenix Inc (SNPX)

[InTheTrenches]

Good summary. Your suggestion to extend the trial should be high on the list of things the company undertakes. I was a bit surprised that the company didn't extend the trial longer last time (as I think you were).

Seems like a few things that need to be addressed:

- Why is placebo doing so well? How to get that group to "behave" more like other trials.

- How to get a better balance in the trial (unusual imbalance in the randomization).

I would still like to see if there is any long-term benefit to going through a washout of memantine. There might be some insight if the company released a subgroup analysis (on-drug vs placebo) of those who weren't on memantine prior to entering the trial.

In addition to extending the trial, both of these issues (placebo and imbalance) should benefit from a larger N (perhaps 300 patients?).